Methylation of the tumor suppressor gene RASSF1A in human tumors

Biochemistry (Mosc). 2005 May;70(5):576-83. doi: 10.1007/s10541-005-0151-y.

Abstract

Loss of heterozygosity of a segment at 3p21.3 is frequently observed in lung cancer and several other carcinomas. We have identified the Ras-association domain family 1A gene (RASSF1A), which is localized at 3p21.3 in a minimum deletion sequence. De novo methylation of the RASSF1A promoter is one of the most frequent epigenetic inactivation events detected in human cancer and leads to silencing of RASSF1A expression. Hypermethylation of RASSF1A was frequently found in most major types of human tumors including lung, breast, prostate, pancreas, kidney, liver, cervical, thyroid and many other cancers. The detection of RASSF1A methylation in body fluids such as serum, urine, and sputum promises to be a useful marker for early cancer detection. The functional analysis of RASSF1A reveals a potential involvement of this protein in apoptotic signaling, microtubule stabilization, and cell cycle progression.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Biomarkers / analysis
  • Chromosomes, Human, Pair 3
  • DNA Methylation*
  • Epigenesis, Genetic*
  • Humans
  • Loss of Heterozygosity
  • Neoplasms / genetics*
  • Tumor Suppressor Proteins / metabolism*
  • Tumor Suppressor Proteins / physiology

Substances

  • Biomarkers
  • RASSF1 protein, human
  • Tumor Suppressor Proteins